ORTX — Orchard Therapeutics Share News
0.000.00%
Last trade - 00:00- $378.06m
- $278.24m
- $22.66m
Brief: Orchard Therapeutics Says $150 Mln Strategic Financing Supports Execution Into First Half Of 2023
Brief: Orchard Therapeutics Announces Interim Data For Otl-203 Showing Positive Clinical Results In Multiple Disease Manifestations Of Mucopolysaccharidosis Type I Hurler Syndrome (Mps-Ih)
Orchard Therapeutics: Guggenheim starts with "buy" on pipeline promise
Brief: Orchard Therapeutics Announces $150 Million Strategic Financing
U.S. STOCKS ON THE MOVE-Halliburton, Tesla, Lithium Americas, Gritstone Oncology
Brief: Orchard Therapeutics Secures Partnerships To Broaden Access To LibmeldyTM For Eligible Patients In Middle East & Turkey
Orchard Therapeutics rises on commercial deals for gene therapy in Middle East, Turkey
U.S. STOCKS ON THE MOVE-Alaska Air, Acacia Communications, Gilead Sciences Inc, Apache Corp
Orchard Therapeutics: Rises after FDA grants 'special' status to gene therapy
Brief: Orchard Therapeutics PLC Expects To File A BLA For Otl-103 In U.S. In 2022
U.S. STOCKS ON THE MOVE-AmerisourceBergen, ReneSola Ltd, Big Tech stocks
Brief: Orchard Therapeutics Receives EC Approval for Libmeldy To Treat Early-Onset Metachromatic Leukodystrophy
Orchard Therapeutics: Rises after gene therapy shows promise in trial
Brief: Orchard Therapeutics Reports OTL-201 Initial Clinical Data In Sanfilippo Syndrome Type A
Brief: Orchard Therapeutics Announces FDA Clearance Of IND Application For OTL-200 For Metachromatic Leukodystrophy
Announces Presentation Of New Otl-201 Clinical Data In Sanfilippo Syndrome Type A (Mps-Iiia)
Brief: Orchard Therapeutics Reports Q3 Loss Per Share $0.20
U.S. STOCKS ON THE MOVE-Pfizer, BioNTech, Navistar, Nikola
U.S. STOCKS ON THE MOVE-Navistar, Boeing, Regeneron, Pfizer